Search

Displaying results 5141 - 5150 of 6835 in total
  1. Drug

    (1H-indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid

    go.drugbank.com/drugs/DB03455
    Experimental

    This compound belongs to the indole-3-acetic acid derivatives. … These are compounds containing an acetic acid (or a derivative) linked to the C3 carbon atom of an indole. (1H-indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid is known to target interleukin-2.

  2. Drug

    Ramosetron

    go.drugbank.com/drugs/DB09290
    Investigational

    Ramosetron is a _serotonin 5-HT3 receptor antagonist_ commonly employed to treat nausea and vomiting, in addition to certain diarrheal conditions. … It is believed to have higher potency and longer antiemetic action than other 1st generation 5-HT3 antagonists such as ondansetron.

  3. Drug

    Ultevursen

    go.drugbank.com/drugs/DB17835
    Investigational

    It was developed by ProQR Therapeutics and is being investigated for the treatment of retinitis pigmentosa.

  4. Drug

    N(4)-Adenosyl-N(4)-methyl-2,4-diaminobutanoic acid

    go.drugbank.com/drugs/DB03458
    Experimental

    This compound belongs to the purine nucleosides and analogues. These are compounds comprising a purine base attached to a sugar.

  5. Drug

    Viral Macrophage-Inflammatory Protein

    go.drugbank.com/drugs/DB15748
    Experimental

    Viral macrophage inflammatory protein-II (vMIP) is a highly basic protein and human chemokine analog encoded by human herpesvirus-8.

  6. Drug

    Procainamide

    go.drugbank.com/drugs/DB01035
    Approved

    A derivative of procaine with less CNS action.

  7. Drug

    Alphaprodine

    go.drugbank.com/drugs/DB13160
    ExperimentalIllicit

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  8. Drug

    Eprodisate

    go.drugbank.com/drugs/DB06405
    Investigational

    Eprodisate slows the decline of renal function in AA amyloidosis.

  9. Drug

    Oxprenolol

    go.drugbank.com/drugs/DB01580
    ApprovedWithdrawn

    A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.

  10. Drug

    GTS-21

    go.drugbank.com/drugs/DB05708
    Investigational

    Athenagen licensed the exclusive rights to the compound and a related library of analogs as part of the acquisition of Osprey Pharmaceutical Company in April 2006.